403 related articles for article (PubMed ID: 11170906)
1. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.
Minari A; Hachem R; Raad I
Clin Infect Dis; 2001 Jan; 32(2):186-90. PubMed ID: 11170906
[TBL] [Abstract][Full Text] [Related]
2. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
[TBL] [Abstract][Full Text] [Related]
3. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Hachem R; Hanna H; Kontoyiannis D; Jiang Y; Raad I
Cancer; 2008 Jun; 112(11):2493-9. PubMed ID: 18412153
[TBL] [Abstract][Full Text] [Related]
4. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome.
Atkinson BJ; Lewis RE; Kontoyiannis DP
Med Mycol; 2008 Sep; 46(6):541-6. PubMed ID: 19180749
[TBL] [Abstract][Full Text] [Related]
5. [Current treatment of candidemia in non-neutropenic patients. Amphotericin B or fluconazole? A retrospective study of 62 consecutive patients].
Cobo Reinoso P; Aguado García JM; Lumbreras Bermejo C; Pérez Vela JL; Caballero Cubedo R; Sanz Sanz F; Noriega Rodríguez AR
Rev Clin Esp; 1997 Dec; 197(12):799-803. PubMed ID: 9477669
[TBL] [Abstract][Full Text] [Related]
6. Candida lusitaniae infections in the era of fluconazole availability.
Hawkins JL; Baddour LM
Clin Infect Dis; 2003 Jan; 36(2):e14-8. PubMed ID: 12522762
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies.
Myoken Y; Kyo T; Fujihara M; Sugata T; Mikami Y
Haematologica; 2004 Mar; 89(3):378-80. PubMed ID: 15020289
[TBL] [Abstract][Full Text] [Related]
8. [Clinical aspects and prognosis of candidemia, a 6-year retrospective study].
Bregenzer T; Evison-Eckstein AC; Frei R; Zimmerli W
Schweiz Med Wochenschr; 1996 Oct; 126(43):1829-33. PubMed ID: 9005522
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
10. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection.
Sipsas NV; Lewis RE; Tarrand J; Hachem R; Rolston KV; Raad II; Kontoyiannis DP
Cancer; 2009 Oct; 115(20):4745-52. PubMed ID: 19634156
[TBL] [Abstract][Full Text] [Related]
11. Breakthrough fungemia caused by azole-resistant Candida albicans in neutropenic patients with acute leukemia.
Myoken Y; Kyo T; Kohara T; Fujihara M; Sugata T; Mikami Y
Clin Infect Dis; 2003 Jun; 36(11):1496-7. PubMed ID: 12766847
[No Abstract] [Full Text] [Related]
12. Two cases of fungemia due to Candida lusitaniae and a literature review.
Viudes A; Pemán J; Cantón E; Salavert M; Ubeda P; López-Ribot JL; Gobernado M
Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):294-9. PubMed ID: 12072941
[TBL] [Abstract][Full Text] [Related]
13. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.
Rex JH; Pappas PG; Karchmer AW; Sobel J; Edwards JE; Hadley S; Brass C; Vazquez JA; Chapman SW; Horowitz HW; Zervos M; McKinsey D; Lee J; Babinchak T; Bradsher RW; Cleary JD; Cohen DM; Danziger L; Goldman M; Goodman J; Hilton E; Hyslop NE; Kett DH; Lutz J; Rubin RH; Scheld WM; Schuster M; Simmons B; Stein DK; Washburn RG; Mautner L; Chu TC; Panzer H; Rosenstein RB; Booth J;
Clin Infect Dis; 2003 May; 36(10):1221-8. PubMed ID: 12746765
[TBL] [Abstract][Full Text] [Related]
14. Fluconazole prophylaxis and Candida fungemia in neutropenic children with malignancies.
Cesaro S; Rossetti F; Perilongo G; Rossi L; Zanesco L
Haematologica; 1993; 78(4):249-51. PubMed ID: 8294059
[TBL] [Abstract][Full Text] [Related]
15. Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies.
Myoken Y; Kyo T; Sugata T; Murayama SY; Mikami Y
Haematologica; 2006 Feb; 91(2):287-8. PubMed ID: 16461328
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological characteristics of fatal Candida krusei fungemia in immunocompromised febrile neutropenic children.
Agirbasli H; Otlu B; Bilgen H; Durmaz R; Gedikoglu G
Infection; 2008 Feb; 36(1):88-91. PubMed ID: 18084719
[No Abstract] [Full Text] [Related]
17. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
Krcmery V; Barnes AJ
J Hosp Infect; 2002 Apr; 50(4):243-60. PubMed ID: 12014897
[TBL] [Abstract][Full Text] [Related]
18. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.
Rex JH; Bennett JE; Sugar AM; Pappas PG; van der Horst CM; Edwards JE; Washburn RG; Scheld WM; Karchmer AW; Dine AP
N Engl J Med; 1994 Nov; 331(20):1325-30. PubMed ID: 7935701
[TBL] [Abstract][Full Text] [Related]
20. Candida glabrata fungemia: experience in a tertiary care center.
Malani A; Hmoud J; Chiu L; Carver PL; Bielaczyc A; Kauffman CA
Clin Infect Dis; 2005 Oct; 41(7):975-81. PubMed ID: 16142662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
